Merit Medical Systems, Inc. · NASDAQ:MMSI

Merit Medical Systems — Merger or Acquisition (June 2023)

14 slides from Merit Medical Systems's merger presentation, Jun 8, 2023

  1. Slide 1: Merit Medical Announces Acquisition of Dialysis Catheter Portfolio, BioSentry and Surfacer

    0 Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc. June 8, 2023

  2. Slide 2: Cautionary Statement Regarding Forward-Looking Statements

    1 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation which are not purely historical, including, without limitation, statements regarding Merit’s forecasted plans, revenues, net sales, net income (GAAP and non-GAAP), operating income and margin (GAAP

  3. Slide 3: Non-GAAP Financial Measures

    2 NON-GAAP FINANCIAL MEASURES Although Merit’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”), Merit’s management believes that certain non-GAAP financial measures provide investors with useful information regard

  4. Slide 4: Compelling Strategic Fit & Value Creation Opportunities

    3 Compelling Strategic Fit & Value Creation Opportunities + Dialysis Catheter Portfolio & BioSentry Biopsy Tract Sealant System Highly Complementary w/ Existing Products & Customers; Leverages Commercial Footprint 1 2 Expands Product Portfolio in Key Strategic Markets Strengthens Competitive Positio

  5. Slide 5: Highly Complementary w/ Existing Products & Customers; Leverages Commercial Footprint

    4 BioFlo EvenMore DuraFlow & DuraFlow 2 Chronic Dialysis DuraMax Peritoneal Dialysis (PD) Catheters DPro ProGuide™ Chronic Dialysis Catheters Centros® & CentrosFLO® Hemodialysis Catheters FirstChoice™ Ultra High-Pressure PTA Balloon Catheters Highly Complementary w/ Existing Products & Customers; Le

  6. Slide 6: Dialysis Portfolio Addressing the Entire ESRD Continuum of Care

    5 Expands Product Portfolio in Key Strategic Markets Dialysis Portfolio Addressing the Entire ESRD Continuum of Care ESRD AV Graft / Fistula Peritoneal Dialysis 1) Per National Institute of Health 6%+ ESRD % of Total Medicare Expenditures1 70%+ On Dialysis1 $37B+ ESRD Medicare Expenditures1 786,000

  7. Slide 7: BioSentry Strengthens Merit Biopsy Portfolio

    6 Expands Product Portfolio in Key Strategic Markets BioSentry Strengthens Merit Biopsy Portfolio 2 Adaptor with Self-Expanding Hydrogel Plus Novel new technology to seal tract following lung biopsy to avoid pneumothorax Dialysis Catheter Portfolio & BioSentry Biopsy Tract Sealant System Full range

  8. Slide 8: Merit Medical Renal Therapies: Offering Life-Saving Options

    7 Merit Medical Renal Therapies | Offering Life-Saving Options Where There Were None Before HeRO® Graft WRAPSODY™ Peritoneal Dialysis Chronic Hemodialysis Renal Accessories Acute Dialysis Chronic Dialysis Surfacer Strengthens Competitive Position in Dialysis and Biopsy Markets; Fueling Long-Term Ren

  9. Slide 9: Compelling Financial Profile

    8 4 Compelling Financial Profile • Acquisition of a portfolio of dialysis catheter products and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. for a total cash consideration of $100 million. • Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascula

  10. Slide 10: Updated FY23 Guidance for Acquisitions; Re-affirm Stand-Alone Guidance

    9 Updated FY23 Guidance for Acquisitions; Re-affirm Stand-Alone MMSI Financial Guidance; FFG Initiatives Remain Priority in 2023 5 • Updated full year 2023 financial guidance now reflects the impacts of the acquisitions of AngioDynamics’ dialysis catheter portfolio and BioSentry® Biopsy Tract Sealan

  11. Slide 11: Appendix: Non-GAAP Financial Measures

    10 Appendix Non-GAAP Financial Measures

  12. Slide 12: Building Upon A History of Successful M&A

    11 Designates Carve-Out Transactions 1) Midpoint of Merit’s 2023 updated revenue guidance Building Upon A History of Successful M&A ($ in millions) $258 $297 $394 $449 $604 $728 $883 $995 $964 $1,237 2009 2010 2012 2013 2016 2017 2018 2019 20231 02/09: Alveolus 06/09: Hatch Medical 05/10: BioSphere

  13. Slide 13: Updated FY23 Guidance for Acquisitions; Re-affirm Stand-Alone Guidance

    12 Updated FY23 Guidance for Acquisitions; Re-affirm Stand-Alone MMSI Financial Guidance; FFG Initiatives Remain Priority in 2023 5 • Updated full year 2023 financial guidance now reflects the forecasted impacts of the acquisition of AngioDynamics’ dialysis catheter portfolio and BioSentry® Biopsy T

  14. Slide 14: 13

    13

Merit Medical Systems — Merger or Acquisition (June 2023) on 6ix